PerkinElmer introduces no-wash immunoassay for mitophagy dysfunction

By The Science Advisory Board staff writers

October 27, 2020 -- PerkinElmer has debuted a no-wash ubiquitin phosphorylation at serine 65 immunoassay for studying defective mitophagy dysfunction associated with Parkinson's and Alzheimer's diseases.

Designed to help scientists discover new therapeutic candidates earlier in the disease cycle, the Cisbio HTRF Phospho-Ubiquitin (Ser65) Cellular Kit makes use of time-resolved fluorescence energy transfer (TR-FRET) technology and provides a "mix and read" approach, according to the company.

The immunoassay is compatible with microplate readers such as the firm's Victor Nivo or EnVision systems. Analysis can be automated and run in high-throughput formats, according to PerkinElmer.

PerkinElmer immunoassay identifies anti-SARS-CoV-2 compounds
PerkinElmer's AlphaLisa immunoassay was used to support global research for effective COVID-19 therapeutics conducted by the National Center for Advancing...
PerkinElmer launches workstations for COVID-19 detection
PerkinElmer has launched a series of new workstations for SARS-CoV-2 testing.
PerkinElmer predicts 12% growth in Q2
PerkinElmer has announced an updated outlook for the second quarter of 2020, predicting 12% revenue growth.
PerkinElmer Q1 revenues edge up, profit edges down
In financial results for the first quarter, PerkinElmer saw revenues grow slightly, but net income slipped.
PerkinElmer launches new workflow tools
PerkinElmer has released a variety of new tools to help pharmaceutical, semiconductor, biomonitoring, and food and material labs improve their testing...

Copyright © 2020

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter